Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04038372
Other study ID # HDVIAHBPI
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 2015
Est. completion date October 2017

Study information

Verified date April 2019
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Globally, about 248 million people are chronic HBV surface antigen carriers, and about 5% of them also had hepatitis delta virus (HDV) infection as well. The prevalence of HBsAg in Egypt is intermediate (2-7%) .

Hepatitis D virus (HDV) is an incomplete RNA virus that needs hepatitis B surface antigen (HBsAg) to help its replication. HDV is considered a subviral particle because it depends on HBV for its propagation. Combined HDV- HBV infection produces more severe liver affection than HBV alone.

HDV infection leads to both of acute and chronic liver illnesses. Acute HDV infection can occur at the same time with acute HBV infection (coinfection) or can be superimposed on the top of chronic HBV infection. About 20% to 30% of coinfections of HDV and HBV in humans develop fatal fulminant hepatitis versus 2% of patients with acute hepatitis B mono-infection. Worldwide, Hepatitis D virus (HDV) infection present in more than 15 million people and it is endemic in the Middle East . In Upper Egypt, data about the prevalence, clinical, laboratory and virological characters of Hepatitis D virus-infected patients is rare.

This study aims were:

1. To estimate the prevalence of hepatitis D virus infection among HBsAg positive individuals.

2. To determine the clinical, laboratory and virological characters of HDV infected patients.


Recruitment information / eligibility

Status Completed
Enrollment 186
Est. completion date October 2017
Est. primary completion date October 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- HBV related liver disorder, aged 18-60 years.

- HBsAg positive individuals were divided into different clinical categories according to EASL 2012 and we revised this classification according to EASL 2017. HBeAg negative chronic infection; HBeAg positive chronic infection), Acute hepatitis, Fulminant hepatitis, Chronic hepatitis (HBeAg positive and HBeAg negative), Liver cirrhosis, and Primary HCC.

Exclusion Criteria:

- Dual infection with other viruses as HCV and/or HIV, auto-immune or alcoholic hepatitis.

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Outcome

Type Measure Description Time frame Safety issue
Primary To determine Anti- HDV prevalence among HBsAg positive individuals. The investigators measured Anti HDV(total) in HBsAg positive cases. Qualitative anti-HDV determination is a competitive assay, based on the ELISA technique (Enzyme-LinkedImmunosorbent), using the methodology described in the man-ufacturer's protocol. ETI-AB-DELTAK-2 (P2808) (Diasorine SPA) Italy. 2 years
Primary To determine the prevalence of hepatitis D virus active infection. The investigators did qualitative measurement of HDV PCR in Anti - HDV positive cases. Real time PCR for HDV RNA was done. 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05797714 - The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT. N/A
Completed NCT02038088 - The Effect of General Anesthesia Immunosuppressive on Hepatitis B Virus Replication N/A
Not yet recruiting NCT06184347 - Population-wide Research for HBV-related Liver Diseases in Maoming City